| 1 2 3 | Impact of State Telehealth Parity Laws for Private Payers on Hypertension Management before and during the COVID-19 Pandemic |
|--|---|
| 4 5 6 7 | Donglan Zhang, PhD ^{1,2*} ; Jun Soo Lee, PhD ^{3*} ; Adebola Popoola, JD, MPH, MBS ³ ; Sarah Lee, BS ¹ ; Sandra L. Jackson, PhD, MPH ³ ; Lisa M. Pollack, PhD, MPH, MPT ³ ; Xiaobei Dong, PhD ⁴ ; Nicole L. Therrien, PharmD, MPH ³ ; and Feijun Luo, PhD ³ |
| 7 8 9 | * Donglan Zhang and Jun Soo Lee are joint 1st authors with equal contributions. |
| 10 11 12 13 14 15 16 17 18 19 | Author Affiliations: ¹ Center for Population Health and Health Services Research, Department of Foundations of Medicine, New York University Grossman Long Island School of Medicine, Mineola, NY ² Department of Population Health, New York University Grossman School of Medicine, New York, NY ³ Division for Health Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, GA ⁴ Joseph J. Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI |
| 20 21 22 23 24 25 26 27 | Correspondence to: Feijun Luo, PhD Economist Division for Health Disease and Stroke Prevention Centers for Disease Control and Prevention Phone: 770-488-3896 Email: <u>hto1@cdc.gov</u> |
| 28 | Word count: abstract: 351; main text: 3,726 |
| 29 30 31 32 | Conflict of Interest Disclosures: None Funding: None |
| 33 34 35 36 37 38 | Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services. |
| 39 40 41 42 43 | Acknowledgments: The authors are genuinely grateful to Michael Schooley (Centers for Disease Control and Prevention) for his guidance, suggestions, and article review. The authors also thank researchers at NORC at the University of Chicago who assisted with collection and coding of state telehealth laws. |

44 Abstract

45 **BACKGROUND**: Telehealth has emerged as an effective tool for managing common chronic

46 conditions such as hypertension, especially during the COVID-19 pandemic. However, the
47 impact of state telehealth payment and coverage parity laws on hypertension management

- 47 Impact of state telenearth payment and coverage parity laws on hypertension mar.48 remains uncertain.
- 49

50 **METHODS**: Data from the MerativeTM MarketScan® Commercial Claims and Encounters

51 Database from January 1, 2016 to December 31, 2021 were used to construct the study cohort.

52 The sample included non-pregnant individuals aged 25–64 years with hypertension. We

reviewed and coded telehealth parity laws related to hypertension management in all 50 states

and the District of Columbia, distinguishing between payment parity laws and coverage parity

55 laws. The primary outcomes were antihypertension medication use, measured by the average

- 56 medication possession ratio (MPR), medication adherence (MPR \geq 80%), and average number of 57 days of drug supply. We used a generalized difference-in-difference (DID) design to examine the
- 57 days of drug supply. We used a generalized difference-in-difference (DID) design to examine the 58 impact of these laws. Results were presented as marginal effects and 95% confidence intervals
- 59 (CI).

6061 **RESULTS**: Among 353,220 individuals, states with payment parity laws were significantly

62 linked to increased average MPR by 0.43 percentage point (95% CI: 0.07 - 0.79), and an increase

63 of 0.46 percentage point (95% CI: 0.06 - 0.92) in the probability of medication adherence.

64 Payment parity laws also led to an average increase of 2.14 days (95% CI: 0.11 - 4.17) in

antihypertensive drug supply, after controlling for state-fixed effects, year-fixed effects,

66 individual sociodemographic characteristics and state time-varying covariates including

67 unemployment rates, GDP per capita, and poverty rates. In contrast, coverage parity laws were

associated with a 2.13-day increase (95% CI: 0.19 - 4.07) in days of drug supply, but did not

69 significantly increase the average MPR or probability of medication adherence. In addition,

telehealth payment or coverage parity laws were positively associated with the number of

71 hypertension-related telehealth visits, but this effect did not reach statistical significance. These

72 findings were consistent in sensitivity analyses.

73

74 CONCLUSIONS: State telehealth payment parity laws were significantly associated with

75 greater medication adherence, whereas coverage parity laws were not. With the increasing

adoption of telehealth parity laws across states, these findings may support policymakers in

vunderstanding potential implications on management of hypertension.

78 Clinical Perspective

79 What Is New?

80

81 Telehealth is an effective tool to manage hypertension and state-level telehealth parity laws can

- 82 influence its application. Prior studies have not clearly differentiated between the impacts of
- payment parity and coverage parity. Using a quasi-experimental generalized difference-in-
- 84 differences design, we assessed the effects of telehealth payment parity and coverage parity laws
- 85 on hypertension management.
- 86
- 87 Our study found that state telehealth payment parity laws were significantly associated with
- 88 increased hypertension medication adherence, while coverage parity laws were not.
- 89

90 What Are the Clinical Implications?

- 91
- 92 The widespread adoption of telehealth payment parity laws may significantly impact
- 93 hypertension management, during emergencies like the COVID-19 pandemic and beyond.
- 94
- 95 Considering that hypertension impacts approximately half of the adult population, our study
- 96 provides valuable insights into the potential benefits of telehealth parity laws for private payers
- 97 in enhancing the management of hypertension.
- 98
- 99 With the increasing adoption of telehealth parity laws across states, integrating telehealth into
- 100 hypertension management holds significant implications for the evolving U.S. healthcare system
- 101 in the digital age.

102 INTRODUCTION

103 The COVID-19 pandemic brought about unprecedented changes in healthcare, leading to 104 a rapid expansion of telehealth services to compensate for deferred medical care. Telehealth 105 emerged as a critical and robust tool in managing prevalent chronic conditions like hypertension.^{1, 2} Telemedicine for hypertension is especially well-received, with one report 106 107 claiming an average adherence to telemedicine-based hypertension management programs as high as 77%.² However, telehealth adoption has been largely influenced by state policies, 108 109 particularly those governing private payers' (otherwise known as private insurance, primarily 110 funded through benefits plans provided by employers) reimbursement. In contrast to public 111 payers like Medicare and Medicaid, private payers covered over half of insured individuals.³ 112 Despite the growing importance of telehealth, little is known about the impact of different state 113 telehealth policies for private payers on hypertension management.

114 Telehealth parity requirements typically fall into two distinct types. The first type is 115 "payment parity," which requires that payments for telehealth services match those for in-person 116 care. Payers must reimburse telehealth services at the same rate or amount as they would for inperson visits.^{4,5} The second type is "coverage parity," which mandates that services covered in-117 118 person must also be covered via telehealth, though not necessarily at an equal amount as in inperson care.^{4, 5} This means the same services are eligible for coverage, but reimbursement rates 119 120 may vary between telehealth and in-person visits. Previous research has explored the association 121 of telehealth parity laws with various outcomes. For example, two studies found that utilization 122 of telehealth services significantly increased in parity versus non-parity states.^{6,7} In addition, 123 studies have shown similar or better clinical outcomes for patients receiving telehealth care compared with in-person care in various clinical settings.^{8,9} However, these studies often 124

125 overlooked the differentiation between "payment parity" and "coverage parity" when 126 investigating the effects of parity. Some states have coverage laws in place, indicating that telehealth services are eligible for coverage, but they might not mandate payment parity, and vice 127 versa.¹⁰ The distinction between these types of parity is crucial, as it can significantly impact 128 129 access to telehealth services and reimbursement rates for healthcare providers. Moreover, prior 130 research on telehealth has been limited to other settings or services, such as mental health care and psychotherapy.^{11, 12} and has not specifically assessed hypertension treatment, particularly for 131 132 private payers.

133 This study aims to fill a gap in the literature by separately investigating the impact of 134 state telehealth payment parity laws and coverage parity laws on hypertension management 135 before and during the COVID-19 pandemic. As outlined in Anderson's behavioral model,¹³ 136 insurance policy serves as a vital enabling factor for physicians to provide essential care to 137 patients with chronic conditions and encourage patients to seek healthcare services. In the 138 context of hypertension management, consistent follow-up for medication prescriptions, 139 conducted via telehealth or in-person consultations, and adhering to antihypertensive medication regimens are key strategies to improve hypertension control.^{14,15} Thus, we hypothesize by 140 141 providing insurance coverage for telehealth services, telehealth parity laws can enhance 142 hypertension management by improving care and medication adherence. Our findings have 143 important implications for policymakers, clinicians, and patients seeking to enhance the use of 144 telehealth for hypertension management.

145 METHODS

146 Data Source

| 147 | We used data from the Merative TM MarketScan [®] Commercial Claims and Encounters |
|-----|---|
| 148 | (CCAE) Database from January 1, 2016 to December 31, 2021. ¹⁶ The MarketScan [®] CCAE |
| 149 | Database comprises patient-level administrative medical and outpatient drug claims, covering |
| 150 | millions of U.S. individuals. The CCAE Database consists of more than 120 large employers and |
| 151 | more than 30 health plans, with 27.5+ and 17.2+ million enrollees in 2016 and 2021, |
| 152 | respectively. The CCAE Database includes claims data for individuals from all 50 U.S. states |
| 153 | and the District of Columbia (DC), although the distribution is uneven across the regions. The |
| 154 | inclusion of unique identifiers in the database allowed for continuous tracking of the same |
| 155 | individuals over time. This study employed secondary data analysis, using de-identified |
| 156 | information; thus, no review by the Institutional Review Board at New York University |
| 157 | Grossman School of Medicine or the Centers for Disease Control and Prevention was deemed |
| 158 | necessary. The authors cannot share the MarketScan® commercial claims database publicly due |
| 159 | to the data user agreement, but the program codes will be available upon request to the |
| 160 | corresponding author. |
| 161 | |

162 Study Sample

163 The study sample included individuals aged 25–64 years as of December 31, 2021. To be

164 included, individuals were required to have had a hypertension diagnosis (International

165 Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM] of I10-I15) during

166 the years 2016–2017, identified as ≥ 1 inpatient or ≥ 2 outpatient visits at least 30 days apart

167 (Appendix Table 1). Furthermore, individuals were required to have had ≥ 1 drug claim for an

168 antihypertensive medication. We identified seven antihypertensive therapeutic classes, including 169 ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, 170 diuretics, renin-angiotensin system antagonists, and other antihypertensives, along with the 171 corresponding generic drug names (Appendix Table 2). 172 To ensure data quality and consistency, we excluded individuals who were not 173 continuously enrolled in a health plan, had a pregnancy-associated diagnosis (Appendix Table 174 1),^{17, 18} or were covered by capitated health insurance (as healthcare utilization and costs are not 175 fully captured among those with capitated health insurance) during our study period (2016 to 176 2021). Participants were also excluded if any state identifiers were missing or unknown. 177 178 **State Telehealth Parity Laws** 179 Using publicly accessible sources (i.e., state agency websites and national organization 180 websites, such as the Center for Connected Health Policy), we reviewed and collected telehealth 181 parity laws (legislations, regulations, executive orders, and agency policies) in the 50 states and 182 Washington, D.C. in effect from January 1, 2018, to December 31, 2021. To ensure that the 183 study adequately assessed the impact of state telehealth parity laws relevant to preventing, 184 treating, and managing hypertension for individuals enrolled in private insurance, we focused on 185 laws that apply to the provision of primary care services and relevant specialty care. These

186 include cardiology, neurology, medication management, cardiac rehabilitation, telestroke, and

187 chronic disease management.

For each state, relevant laws were independently coded by two researchers, and
discrepancies in coding were resolved through discussions and consensus. Coding of telehealth
coverage and payment parity laws were based on the legal language in each state. A parity law

| 191 | was coded as "payment parity" if it expressly required private payers to reimburse telehealth |
|-----|--|
| 192 | services at the same rate as an in-person visit (e.g., reimbursement for services provided through |
| 193 | telehealth must be equivalent to reimbursement for the same services provided in-person). |
| 194 | Similarly, a parity law was coded as "coverage parity" if it contained language expressly |
| 195 | requiring private payers to cover the same services for telehealth as if it would have been |
| 196 | covered for an in-person visit (e.g., shall provide coverage for services provided via telehealth if |
| 197 | it was covered in-person and shall be subject to the same terms and conditions, but coverage |
| 198 | parity does not guarantee the same rate of payment). |
| 199 | The state law analysis did not assess laws for specialty services not commonly associated |
| 200 | with hypertension, stroke, or cardiovascular disease. These include mental health services, |
| 201 | hospice, and palliative care. The coded telehealth laws (Appendix Table 3) were then linked to |
| 202 | our study sample using state identifiers. |
| 203 | |
| 204 | Outcomes |
| 205 | The primary outcomes of the study included antihypertensive medication use, measured |
| 206 | by the three indicators: 1) average medication possession ratio (MPR) of antihypertensive drugs, |

207 2) medication adherence to antihypertensive drugs (defined as MPR \geq 80%), and 3) average

208 number of days of antihypertensive drug supply. Additionally, as secondary outcome measures,

209 we included the number of hypertension-related and cardiovascular disease (CVD)-related

210 telehealth visits.

To calculate the average MPR, we estimated the means of the MPRs for the seven antihypertensive therapeutic classes (Appendix Table 2). Each MPR was computed as the ratio of the total days of antihypertensive drug supply to the number of days in each year.¹⁹ A patient

was assessed as adherent if the average MPR was $\geq 80\%$.¹⁹ The average days of drug supply 214 215 referred to the average number of pills of medication supplied per antihypertensive prescription. 216 Telehealth outpatient visits were defined if outpatient visits were telehealth-related using 217 place of service and procedure modifiers (Appendix Table 4). In-person outpatient visits were 218 defined as non-telehealth-related outpatient visits. Telehealth visits can be complementary to in-219 person care whereby in-person visits might increase follow-up telehealth appointments, or telehealth visits might result in a necessary in-person visit.²⁰ In addition, telehealth can be a 220 221 substitute to in-person services, such as a telehealth visit substituting an in-person visit during the pandemic.²¹ Therefore, we adjusted for the number of in-person visits when assessing 222 223 telehealth visits as an outcome, and vice versa. Hypertension- and CVD-related telehealth 224 outpatient visits were identified if telehealth outpatient visits included the respective diagnosis 225 (Appendix Table 1). All outcomes were assessed on a per patient per year basis, providing a 226 comprehensive analysis of hypertension management and telehealth utilization.

227

228 Statistical Analysis

To estimate the association between telehealth parity laws and hypertension management, we used a generalized difference-in-difference (DID) design with different treatment timing.²² Given that telehealth parity laws were in effect in different states during various time periods, we utilized the different timing of these laws to estimate the generalized DID effects. Within the generalized DID methodology, we used linear regression for average MPR, logistic regression for medication adherence, and negative binomial regression for numbers of days of antihypertensive drug supply; we used exponential hurdle²³ model for number of hypertension-

and CVD-related telehealth outpatient visits, since some patients may have zero telehealth visitsin a year (e.g., excess zeros in the outcome measure).

238 In sensitivity analyses to test the influence of different model setups on the estimated 239 results we used Probit and linear models for medication adherence. For the number of days of 240 antihypertensive drug supply, we used a zero-inflated negative binomial model. This approach 241 accommodates patients with zero days of drug supply by combining a logit model for zero 242 outcomes and a negative binomial model for the average number of days of drug supply. 243 All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis 244 (claims with ICD-10-CM of U07.1), number of in-person visits, age groups (18–34 [reference], 245 35–44, 45–54, and 55–64 years), sex (male [reference], female), urbanicity of residence (urban [reference], rural, per US Census Metropolitan Statistical Area [MSA] designation),¹⁶ and 17 246 Quan-Charlson comorbidities.²⁴ Comorbidities were identified as present if individuals had ≥ 1 247 248 inpatient admission or ≥ 2 outpatient encounters (≥ 30 days apart) with the corresponding Quan-249 Charlson ICD-10-CM diagnoses. In addition, state-year level time-varying covariates such as 250 state-year level unemployment rates, GDP per capita, and poverty rates were included in the 251 models. We reported the average marginal effects along with 95% confidence intervals (CI). To 252 account for potential clustering effects, all standard errors were clustered by state. All outcomes 253 are measured on a per patient per year basis, except for the number of telehealth visits, measured 254 as per 1,000 patients per year.

Two-tailed *p*-values < 0.05 were used to indicate statistical significance. All the analyses were conducted using Stata SE 17.0 statistical software (StataCorp, College Station, TX) and SAS version 9.4 (SAS 9.4, Cary, NC. SAS Institute Inc.).

258 **RESULTS**

| 259 | There were 353,220 included individuals (Figure 1). The sociodemographic |
|-----|--|
| 260 | characteristics of the study cohort at baseline are summarized in Table 1. The average age of |
| 261 | patients with hypertension was 49.5 (SD, 7.1) years. Women comprised 45.55% of the cohort, |
| 262 | and 84.19% lived in urban areas. Baseline medication adherence fluctuated between 57.54% and |
| 263 | 60.50% from 2018 to 2021. The most prevalent comorbidities during the lookback period (2016– |
| 264 | 2017) included diabetes without chronic complications (22.77%), chronic pulmonary disease |
| 265 | (8.00%), diabetes with chronic complications (4.83%), any malignancy (3.42%), and renal |
| 266 | disease (3.26%). The distribution of the patient cohort in each state is presented in Appendix |
| 267 | Table 5. |
| 268 | In 2018, one state had a payment parity law, 20 had coverage parity laws, and 6 had both. |
| 269 | By 2021, these values had increased to 5 states with payment parity laws, 24 with coverage |
| 270 | parity laws, and 16 with both. |
| 271 | After controlling for potential confounders, states with a payment parity law saw a |
| 272 | statistically significant 0.43 percentage point (95% CI: 0.07 - 0.79) increase in average MPR |
| 273 | among individuals with hypertension (Table 2). Furthermore, the payment parity law was |
| 274 | significantly associated with a 0.46 percentage point (95% CI: 0.00 - 0.92) increase in the |
| 275 | probability of medication adherence and a significant increase in average days of |
| 276 | antihypertensive drug supply by 2.14 days (95% CI: 0.11 - 4.17) per patient per antihypertensive |
| 277 | prescription. |
| 278 | Coverage parity laws were not significantly associated with average MPR or medication |
| 279 | adherence, but were associated with a significant increase in average days of antihypertensive |
| 280 | drug supply by 2.13 days (95% CI: 0.19 - 4.07) per patient per antihypertensive prescription. |

| 281 | Payment parity laws were associated with a significant increase in the number of |
|-----|--|
| 282 | hypertension-related telehealth visits by 2.61 visits per 1,000 patients (95% CI: 0.99 - 4.23) and |
| 283 | CVD-related telehealth visits by 0.92 visits per 1,000 patients (95% CI: 0.23 - 1.61) (Appendix |
| 284 | Table 6). On the other hand, coverage parity laws did not show a statistically significant |
| 285 | association with the number of telehealth visits (Appendix Table 7). |
| 286 | In sensitivity analyses, we tested different model setups (Probit and linear regression) for |
| 287 | the medication adherence measure, and the results remained largely unchanged (Appendix Table |
| 288 | 8). Moreover, when using the zero-inflated negative binomial model for the average days of drug |

supply, the association with state payment parity was positive, but not statistically significant

290 (Appendix Table 9).

291

292 DISCUSSION

293 This study comprehensively assessed the potential impact of telehealth parity laws on 294 hypertension management before and during the COVID-19 pandemic among private payers 295 across the 50 states and DC. We distinguished between payment parity and coverage parity, as 296 these different types of parity laws could have differential impact on patient access and behavior. 297 Interestingly, the results revealed that state payment parity laws for hypertension-related 298 telehealth services were significantly associated with increased average MPR, adherence to 299 antihypertensive medications, and average days of drug supply. However, coverage parity laws 300 were not found to be significantly associated with average MPR or medication adherence, but 301 significantly associated with increased average days of drug supply. Furthermore, both types of 302 parity laws did not significantly influence the numbers of hypertension-related telehealth visits or

in-person visits during the study period. These findings remained robust after using alternativemodels in sensitivity analyses.

305 Applying a quasi-experimental generalized DID design, one key finding of our study was 306 that telehealth payment parity laws were associated with significant improvements in medication 307 adherence among patients with hypertension. It is possible that telehealth visits facilitated 308 hypertension management by improving continuity of care, such as by alleviating patient 309 concerns about exposure to SARS-CoV-2, the virus that causes COVID-19, during in-person 310 office visits. In a recent study, Patel et al. (2020) estimated that the overall volume of care for hypertension dropped by 23.0% at the outset of the pandemic.²⁵ Delayed care could lead to 311 312 worsened outcomes for patients with poorly controlled hypertension, including heart attacks, coronary heart disease, strokes, and kidney damage.²⁶ Consequently, telehealth use surged to 313 314 ensure patient access to medical care without compromising patient and clinician safety. Though 315 the marginal effect of 0.46 percentage point increase in the probability of medication adherence 316 we observed seemed modest, considering that approximately 48 million individuals aged 20-64 317 have high blood pressure and are currently taking an antihypertensive medication, of whom 66.0% are covered by private insurance (as per NHANES 2017–2018 data).²⁷ nationwide 318 319 adoption of telehealth payment parity laws across all states could potentially result in 320 approximately 145,728 more individuals achieving adherence to antihypertensive medications 321 (MPR \geq 80%). State telehealth payment parity laws were associated with immediate and positive 322 impacts on populations affected by hypertension during the COVID-19 pandemic, especially 323 given that telehealth usage has been associated with significant improvements in blood pressure control.28 324

325 Previous evidence-based studies suggest that an effective telehealth model for 326 hypertension management should incorporate self-measured blood pressure monitoring or remote patient monitoring (RPM) that requires patients to record blood pressure outside of 327 clinical settings and share the data with their clinicians.²⁹ Another essential component of a 328 329 telehealth visit includes consultations on the proper use of antihypertensive medications and 330 adherence to medication regimens, and health education regarding lifestyle changes, often delivered through Internet video teleconferences on mobile devices.² This approach may be 331 332 combined with team-based care to provide this array of follow up services by a multidisciplinary team including physicians, nurses, health coaches, and pharmacists.³⁰ But this combined 333 334 approach may not always be practical, due to challenges such as patient access to digital 335 platforms, reliable internet connection, and availability of compatible devices for vital sign measurement and transmission.³¹⁻³³ To address these limitations, more simplified versions of 336 337 telehealth, such as audio-only phone-based services, text messaging (SMS), or emails have also 338 emerged as alternatives for communication that may still support treatment adherence and symptom surveillance.³⁴⁻³⁶ Some states have passed laws allowing reimbursement for audio-only 339 340 services, primarily for the state Medicaid program, catering to the needs of patients with lower incomes who might lack smartphones or digital connectivity.^{32,34} Future studies could explore 341 342 the influence of these laws on hypertension management.

We found that telehealth coverage parity laws were significantly associated with an increase in the average days of antihypertensive drug supply, but did not improve medication adherence. This could, in part, be attributed to telehealth coverage parity solely confirming insurance coverage without ensuring consistent reimbursement structures. Telehealth coverage parity alone can result in patients incurring higher out-of-pocket costs for telehealth services.

348 Another possibility is that coverage parity laws may influence clinician behavior. For instance, if 349 the reimbursement rates for telehealth are lower, healthcare systems or clinicians may reduce the 350 number of telehealth appointments offered and extend the duration of prescriptions for patients. 351 As shown in our study, more states adopted telehealth coverage parity or both parity laws 352 rather than only payment parity laws. A recent review provides a comparative analysis of state-353 by-state adoption of telehealth parity, highlighting the need for alternative payment models, assessing resource utilization, and considering costs linked to virtual care.⁸ Certainly, looking 354 355 beyond the pandemic, integrating telehealth into hypertension management without increasing utilization of telehealth may demand innovative payment models and care quality metrics.³⁷ 356 357 In the present study, we found a significant association between telehealth payment parity 358 laws and the number of hypertension- and CVD-related telehealth visits. This finding was 359 consistent with previous research. For example, a study analyzing 2010–2015 MarketScan® 360 commercial claims data observed significant increases in outpatient telehealth visits in states with parity laws.⁶ Another study demonstrated enrollees in states with private payer telehealth 361 laws were more likely to receive video assessments.⁷ However, our study did not find that 362 363 telehealth coverage laws alone were significantly associated with the number of telehealth visits. 364 Compared with prior studies, our study specifically examined the impact of these laws during the 365 pandemic period, and focused on the laws relevant to hypertension and CVD management. 366 These methodological and contextual differences may account for the differences in our findings.²⁵ 367

There are several key strengths of this study. First, unlike prior research that did not distinguish between the effects of payment parity laws and coverage parity laws, we contributed to the literature by evaluating the net impact of these two types of laws individually and teasing out their effects separately while providing a more comprehensive understanding of the impact
of state laws governing private payer reimbursements for telehealth services. Second, while
previous parity law studies predominantly centered around mental health services, our focus was
on relevant laws affecting hypertension management and control, filling a critical research gap.
Third, the variation in state policies across different years posed a challenge to the traditional
DID analysis; thus, we used a generalized DID approach, which is a more advanced and flexible
method to evaluate policy impacts.

378 There are a few limitations in our study. First, for the state law analysis, we identified and 379 collected telehealth parity laws from secondary sources. Some relevant laws may have been 380 missed because they were unavailable, used vague language, or were missing key information 381 (such as legal citations). In instances where effective dates were missing, the dates were 382 represented by a proxy date using January 1 of the respective year. Nevertheless, we believe that 383 this should not significantly affect our analysis. For instance, if the law was implemented at the 384 end of the year, our analysis was based on the data for that specific year, which may even make 385 our estimates conservative. Second, some states might have implemented temporary telehealth 386 COVID-19 emergency policies that were difficult to search for online, or may have expired 387 during the study period. However, we did not include these policies in the treatment group and 388 focused our analysis on permanent laws rather than temporary policies. Third, apart from 389 telehealth parity laws, another important regulatory aspect at the state level is licensure requirements, ³⁸ which can potentially influence the impact of parity laws on hypertension 390 391 management. Some states have adopted interstate telemedicine laws, while others mandate registration for such practices.^{3,8,9} Language barriers and costs of telehealth infrastructure may 392 393 hinder implementation. Additionally, varying state policies impact the rates of hospital telehealth

adoption,³ and private payer reimbursement policies correlating with higher adoption rates. None 394 395 of these factors were considered in the current analysis, as they fell outside the scope of the 396 study. Fourth, although the MarketScan[®] commercial claims database provides a national 397 sample that has comprehensive geographical representation covering all 50 states and D.C., there 398 might be variations in the study population selected from different states. Nevertheless, this 399 limitation has been mitigated through the adjustment for state fixed effects and state-level time-400 varying variables. Fifth, we did not assess whether participants relocated from one state to 401 another during the study period. Since our sample selection criteria required continuous 402 enrollment of participants during the study period, participants who moved were likely excluded 403 from our study cohort.

404

405 CONCLUSION

406 Our findings suggest that state telehealth payment parity laws may be significantly 407 associated with hypertension treatment based on increased related telehealth visits and 408 medication adherence. However, coverage parity laws alone do not have a significant association 409 with telehealth services or medication adherence. Future studies could assess the associations of 410 state telehealth laws for public payers and uninsured groups, as well as how licensure 411 requirements are associated with hypertension management. Given that hypertension affects 412 roughly half of the adult population, our study holds significant implications for the evolving U.S. healthcare system in the digital age.³⁹ Our results offer insights into the potential role of 413 414 telehealth parity laws for private payers in facilitating hypertension management.

Mabeza RMS, Maynard K and Tarn DM. Influence of synchronous primary care

systematic review. BMC primary care. 2022;23:1-10.

telemedicine versus in-person visits on diabetes, hypertension, and hyperlipidemia outcomes: a

415 **REFERENCES**

1.

- 416
- 417 418

419

420

421 Omboni S, McManus RJ, Bosworth HB, Chappell LC, Green BB, Kario K, Logan AG, 2. 422 Magid DJ, Mckinstry B and Margolis KL. Evidence and recommendations on the use of 423 telemedicine for the management of arterial hypertension: an international expert position 424 paper. Hypertension. 2020;76:1368-1383. 425 Adler-Milstein J, Kvedar J and Bates DW. Telehealth among US hospitals: several 3. 426 factors, including state reimbursement and licensure policies, influence adoption. Health Affairs. 2014;33:207-215. 427 428 4. Nicol Turner Lee JK and Roberts J. Removing regulatory barriers to telehealth before 429 and after COVID-19. Brookings Institution. 2020. 430 Faget KY, Boubker, J. Legal considerations. In Emerging Practices in Telehealth: Academic Press; 5. 431 2023: 77-96. 432 Harvey JB, Valenta S, Simpson K, Lyles M and McElligott J. Utilization of outpatient 6. 433 telehealth services in parity and nonparity states 2010–2015. Telemedicine and e-Health. 434 2019;25:132-136. 435 Lee H and Singh GK. The Impact of Telemedicine Parity Requirements on Telehealth 7. 436 Utilization in the United States During the COVID-19 Pandemic. Journal of Public Health 437 Management and Practice. 2023;29:E147-E156. 438 8. Khera N, Knoedler M, Meier SK, TerKonda S, Williams RD, Wittich CM, Coffey JD and 439 Demaerschalk BM. Payment and Coverage Parity for Virtual Care and In-Person Care: How Do 440 We Get There? Telemedicine Reports. 2023;4:100-108. 441 Totten AM, Hansen RN, Wagner J, Stillman L, Ivlev I, Davis-O'Reilly C, Towle C, 9. 442 Erickson JM, Erten-Lyons D and Fu R. Telehealth for acute and chronic care consultations. 443 2019. 444 10. Center for Connected Health Policy. Parity requirements for private payer telehealth 445 services. 2023;2023. 446 Gliske K, Berry KR, Ballard J, Evans-Chase M, Solomon PL and Fenkel C. Mental health 11. 447 outcomes for youths with public versus private health insurance attending a telehealth intensive 448 outpatient program: quality improvement analysis. JMIR Formative Research. 2022;6:e41721. 449 Amill-Rosario A, Rose R and dosReis S. Impact of Private Payer Policies on the 12. 450 Transition to Telemental Health Care Among Privately Insured Patients with Mental Health 451 Disorders. Telemedicine and e-Health. 2023. 452 Andersen RM, Rice TH and Kominski GF. Changing the US health care system: Key 13. 453 issues in health services policy and management. John Wiley & Sons; 2011. 454 Granger BB and Bosworth H. Medication adherence: emerging use of technology. 14. 455 Current opinion in cardiology. 2011;26:279. 456 Kini V and Ho PM. Interventions to improve medication adherence: a review. Jama. 15. 457 2018;320:2461-2473. 458 16. Merative MarketScan® Research Databases. 459 https://marketscan.truvenhealth.com/marketscanportal. Accessed April 14, 2023. 460 Kuklina EV, Tong X, Bansil P, George MG and Callaghan WM. Trends in pregnancy 17. 461 hospitalizations that included a stroke in the United States from 1994 to 2007: reasons for 462 concern? Stroke. 2011;42:2564-2570.

Lee JS, MacLeod KE, Kuklina EV, Tong X and Jackson SL. Social Determinants of 463 18. 464 Health–Related Z Codes and Health Care Among Patients With Hypertension. AJPM Focus. 465 2023;2:100089. 466 19. Canfield SL, Zuckerman A, Anguiano RH, Jolly JA, DeClercg J, Wascher M, Choi L, 467 Knox S and Mitchell DG. Navigating the wild west of medication adherence reporting in 468 specialty pharmacy. J Manag Care Spec Pharm. 2019;25:1073-1077. 469 20. Chao GF, Li KY, Zhu Z, McCullough J, Thompson M, Claflin J, Fliegner M, Steppe E, 470 Ryan A and Ellimoottil C. Use of telehealth by surgical specialties during the COVID-19 471 pandemic. JAMA surgery. 2021;156:620-626. 472 Cao Y, Chen D and Smith M. Use telehealth as needed: telehealth substitutes in-person 21. 473 primary care and associates with the changes in unplanned events and follow-up visits. BMC 474 Health Services Research. 2023;23:426. 475 Richardson DB, Ye T and Tchetgen Tchetgen EJ. Generalized Difference-in-Differences. 22. 476 Epidemiology. 2023;34:167-174. 477 Cragg JG. Some statistical models for limited dependent variables with application to the 23. 478 demand for durable goods. Econometrica: journal of the Econometric Society. 1971:829-844. 479 Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck 24. 480 CA, Feasby TE and Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and 481 ICD-10 administrative data. Med Care. 2005:1130-1139. 482 25. Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I and Barnett ML. 483 Variation in telemedicine use and outpatient care during the COVID-19 pandemic in the United 484 States: study examines variation in total US outpatient visits and telemedicine use across 485 patient demographics, specialties, and conditions during the COVID-19 pandemic. Health Aff 486 (Millwood). 2021;40:349-358. 487 26. CDC. National Center for Chronic Disease Prevention and Health Promotion, Division for 488 Heart Disease and Stroke Prevention. Facts About Hypertension. 2023. 489 Rana J, Oldroyd J, Islam MM, Tarazona-Meza CE and Islam RM. Prevalence of 27. 490 hypertension and controlled hypertension among United States adults: evidence from NHANES 491 2017-18 survey. International Journal of Cardiology Hypertension. 2020;7:100061. 492 Jackson TN, Sreedhara M, Bostic M, Spafford M, Popat S, Lowe Beasley K, Jordan J 28. 493 and Ahn R. Telehealth Use to Address Cardiovascular Disease and Hypertension in the United 494 States: A Systematic Review and Meta-Analysis, 2011–2021. Telemedicine Reports. 2023;4:67-495 86. 496 29. Kario K. Management of hypertension in the digital era: small wearable monitoring 497 devices for remote blood pressure monitoring. Hypertension. 2020;76:640-650. 498 30. Jacob V, Chattopadhyay SK, Proia KK, Hopkins DP, Reynolds J, Thota AB, Jones CD, 499 Lackland DT, Rask KJ and Pronk NP. Economics of self-measured blood pressure monitoring: a 500 community guide systematic review. American journal of preventive medicine. 2017;53:e105-501 e113. 502 31. Zhang D, Shi L, Han X, Li Y, Jalajel NA, Patel S, Chen Z, Chen L, Wen M and Li H. 503 Disparities in telehealth utilization during the COVID-19 pandemic: Findings from a nationally 504 representative survey in the United States. Journal of Telemedicine and Telecare. 505 2021:1357633X211051677. 506 32. Kuziemsky C, Hunter I, Udayasankaran JG, Ranatunga P, Kulatunga G, John S, John 507 O, Flórez-Arango JF, Ito M and Ho K. Telehealth as a means of enabling health equity. 508 Yearbook of Medical Informatics. 2022;31:060-066. 509 33. Omboni S, Padwal RS, Alessa T, Benczúr B, Green BB, Hubbard I, Kario K, Khan NA, 510 Konradi A and Logan AG. The worldwide impact of telemedicine during COVID-19: current 511 evidence and recommendations for the future. Connected health. 2022;1:7. 512 Odukoya EJ, Andino J, Ng S, Steppe E and Ellimoottil C. Predictors of Video versus 34. 513 Audio-Only Telehealth Use among Urological Patients. Urology practice. 2022;9:198-204.

514 35. Tam HL, Wong EML, Cheung K and Chung SF. Effectiveness of text messaging
515 interventions on blood pressure control among patients with hypertension: systematic review of
516 randomized controlled trials. *JMIR mHealth and uHealth*. 2021;9:e24527.

517 36. Berrouiguet S, Baca-García E, Brandt S, Walter M and Courtet P. Fundamentals for 518 future mobile-health (mHealth): a systematic review of mobile phone and web-based text 519 messaging in mental health. *Journal of medical Internet research*. 2016;18:e135.

520 37. Dinesen B, Nonnecke B, Lindeman D, Toft E, Kidholm K, Jethwani K, Young HM, 521 Spindler H, Oestergaard CU and Southard JA. Personalized telehealth in the future: a global 522 research agenda. *Journal of medical Internet research*. 2016;18:e53.

523 38. Adams AJ. Facilitating multistate pharmacy practice: streamlining continuing pharmacy 524 education requirements. *Journal of the American Pharmacists Association*. 2023;63:731-735.

525 39. Chobufo MD, Gayam V, Soluny J, Rahman EU, Enoru S, Foryoung JB, Agbor VN,

526 Dufresne A and Nfor T. Prevalence and control rates of hypertension in the USA: 2017–2018. 527 International Journal of Cardiology Hypertension. 2020;6:100044.

529 Figure 1. Study sample selection of patients with hypertension, MarketScan[®] Commercial 530 Claims and Encounters Database, 2016–2021. 531 532 Patients aged 25-64 (as of Dec 31, 2021; last 533 follow-up time point) ^a enrolled in a 534 commercial health insurance plan and had ≥ 1 535 inpatient or ≥ 2 outpatient visits with at least 30 536 days interval - hypertension diagnosis (ICD-10-537 CM=I10-I15) in 2016-2017 (n=2,738,683) 538 539 No antihypertensive medication history 540 in 2016 (n=283,876 [10%]) 541 542 Patients with at least one drug claim of 543 antihypertensive medication in 2016–2017 544 (n=2,454,807 [90%]) 545 Not continuously enrolled 546 (n=1,827,953 [74%]) 547 548 Continuously enrolled in 2016–2021 549 (n = 626, 854 [26%])550 551 552 Pregnancy associated diagnosis (n=6,620[1%])553 554 No pregnancy associated diagnosis in 2016-555 2021 (n = 620,234 [99%])556 557 Capitated insurance 558 (n=166,499 [27%]) 559 Non-capitated insurance in 2016–2021 560 (n = 453,735 [73%])561

Missing or unknown state identifiers ^b (n=100,515 [22%])

565 566 567

568 569

562

563

564

Abbreviation: ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification

Non-missing state identifiers (50 states + DC) (n = 353,220 [78%])

^a Age was calculated as of December 31, 2021, the ending period of the sample period, to exclude patients diagnosed
 with AF before aged 65, but became 65+ during the sample periods.

^b Of the 100,515 patients, 100,382 had unknown state information, 7 had Puerto Rico state information, and 126 had
 missing state information.

- 574
- 575

576 Table 1. Baseline Characteristics of patients with hypertension in MarketScan®

577 Commercial Claims and Encounters Database, 2016–2021.

578

| | N=353,220 |
|--|------------------|
| Baseline Characteristics | |
| Age, mean (SD) | 49.5 (7.1) |
| Age groups, n (%) | |
| 18–34 | 14,695 (4.16%) |
| 35–44 | 64,651 (18.30%) |
| 45–54 | 168,706 (47.76%) |
| 55–64 | 105,168 (29.77%) |
| Female, n (%) | 160,903 (45.55%) |
| Urban Residency, n (%) | 297,364 (84.19%) |
| Census regions, n (%) | |
| Northeast | 48,266 (13.66%) |
| Midwest | 84,284 (23.86%) |
| South | 186,515 (52.80%) |
| West | 33,495 (9.48%) |
| Baseline medication adherence ^a , n (%) | |
| Year 2018 | 205,869 (58.28%) |
| Year 2019 | 203,227 (57.54%) |
| Year 2020 | 213,715 (60.50%) |
| Year 2021 | 209,405 (59.28%) |
| Comorbidities in lookback periods (2016– | |
| 2017), n (%) | |
| Myocardial infarction | 5,995 (1.70%) |
| Congestive heart failure | 8,521 (2.41%) |
| Cerebrovascular | 6,841 (1.94%) |
| Peripheral vascular | 2,708 (0.77%) |
| Dementia | 100 (0.03%) |
| Chronic pulmonary disease | 28,266 (8.00%) |
| Rheumatic disease | 5,929 (1.68%) |
| Peptic ulcer disease | 1,286 (0.36%) |
| Mild liver disease | 9,995 (2.83%) |
| Diabetes without chronic complication | 80,424 (22.77%) |
| Diabetes with chronic complication | 17,067 (4.83%) |
| Hemiplegia or paraplegia | 1,137 (0.32%) |
| Renal disease | 11,517 (3.26%) |
| Any malignancy | 12,081 (3.42%) |
| Moderate or severe liver disease | 516 (0.15%) |
| Metastatic solid tumor | 1,137 (0.32%) |
| AIDS/HIV | 1.075 (0.30%) |

579

^a Medication adherence was defined as a dummy indicator, where = 1 if the average medication

581 possession ratio of the seven antihypertensive therapeutic classes is $\geq 80\%$, otherwise = 0.

582 Table 2. The association of <u>telehealth payment parity laws</u> with medication adherence,

medication possession ratios, and average number of drug supply per antihypertensive
 drug, 2018–2021.^a

| | Average Medication Possession Ratios | Medication Adherence (%) ^b | Average days of drug supply |
|----------------------------|--|--|--------------------------------|
| Payment parity | 0.43* (0.07 - 0.79) | 0.46* (0.00 - 0.92) | 2.14* (0.11 - 4.17) |
| Covariates | | | |
| COVID-19 diagnosis | -1.69*** | -3.57*** | -2.19*** |
| | (-1.951.42) | (-4.023.11) | (-3.121.27) |
| Number of in-person visits | 0.05*** | 0.00 | -0.15*** |
| | (0.04 - 0.07) | (-0.00 - 0.00) | (-0.170.13) |
| Aged 18–34 [reference] | | | |
| Aged 35–44 | 9.83*** | 9.33*** | 16.96*** |
| _ | (9.09 - 10.57) | (8.56 – 10.1) | (15.69 - 18.23) |
| Aged 45–54 | 17.07*** | 17.90*** | 27.04*** |
| | (16.33 - 17.82) | (17.10 - 18.60) | (25.49 - 28.59) |
| Aged 55–64 | 21.21*** | 23.90*** | 31.55*** |
| C | (20.31 - 22.11) | (23.00 - 24.70) | (29.40 - 33.70) |
| Male [reference] | | | |
| Female | -2.93*** | -3.95*** | -9.20*** |
| | (-3.252.60) | (-4.363.54) | (-10.168.24) |
| Rural [reference] | · · · · · · · · · · · · · · · · · · · | | |
| Urban | 0.24 | -0.41 | 6.98*** |
| | (-0.34 - 0.81) | (-1.09 - 0.269) | (3.50 - 10.47) |
| Comorbidities | | | |
| Myocardial infarction | -1.57*** | -0.81 | -18.46*** |
| · | (-2.410.73) | (-1.92 - 0.309) | (-20.0116.90) |
| Congestive heart failure | -1.24*** | -2.88*** | -23.52*** |
| 5 | (-1.850.63) | (-3.712.05) | (-25.1321.90) |
| Cerebrovascular | -0.75* | -0.857 | -10.18*** |
| | (-1.380.11) | (-1.73 - 0.01) | (-11.349.013) |
| Peripheral vascular | -3.03*** | -2.97*** | -13.01*** |
| - | (-4.391.66) | (-4.471.46) | (-15.5310.49) |
| Dementia | -11.15** | -10.00** | -33.00*** |
| | (-17.834.47) | (-16.703.33) | (-44.9021.10) |
| Chronic pulmonary | -2.71*** | -3.46*** | -6.38*** |
| disease | (-3.162.25) | (-4.002.93) | (-7.265.49) |
| Rheumatic disease | -1.57*** | -2.26*** | -4.50*** |
| | (-2.410.74) | (-3.291.22) | (-6.332.66) |
| Peptic ulcer disease | -7.84*** | -9.36*** | -16.52*** |
| | (-9.186.49) | (-11.007.70) | (-19.9513.09) |

| | 2 70*** | 0.40*** | (10+++ |
|------------------------------|----------------|----------------|----------------|
| wind liver disease | -2./9*** | -2.42*** | -0.12*** |
| | (-3.512.06) | (-3.361.48) | (-7.904.34) |
| Diabetes without chronic | 1.60*** | 1.46*** | 8.56*** |
| complication | (1.34 - 1.87) | (1.07 - 1.85) | (7.73 - 9.39) |
| Diabetes with chronic | -1.37*** | -2.04*** | -1.64*** |
| complication | (-1.830.91) | (-2.671.42) | (-2.390.88) |
| Hemiplegia or paraplegia | -3.63** | -2.73* | -13.37*** |
| | (-6.320.93) | (-5.180.28) | (-19.097.64) |
| Renal disease | -0.24 | -2.01*** | -14.09*** |
| | (-0.84 - 0.35) | (-2.721.31) | (-15.9112.28) |
| Any malignancy | 0.72 | 1.66*** | -0.11 |
| | (-0.01 - 1.46) | (0.85 - 2.47) | (-1.49 - 1.27) |
| Moderate or severe liver | -7.14*** | -9.99*** | -36.23*** |
| disease | (-11.073.20) | (-14.06.01) | (-43.1829.29) |
| Metastatic solid tumor | -7.11*** | -7.11*** | -13.71*** |
| | (-8.635.59) | (-8.995.22) | (-18.758.68) |
| AIDS/HIV | 2.35** | 2.94*** | -7.882*** |
| | (0.62 - 4.07) | (1.19 - 4.70) | (-11.783.98) |
| State-year level covariates | | | |
| Unemployment rates | 0.19* | 0.32** | -0.12 |
| | (0.03 - 0.35) | (0.08 - 0.56) | (-0.80 - 0.56) |
| GDP per capita | -0.00 | -0.00 | -0.00 |
| | (-0.00 - 0.00) | (-0.00 - 0.00) | (-0.00 - 0.00) |
| Poverty rates | 0.01 | 0.00 | -0.17 |
| | (-0.11 - 0.13) | (-0.11 - 0.18) | (-0.41 - 0.07) |
| | | | |
| State fixed effects | Yes | Yes | Yes |
| Year fixed effects | Yes | Yes | Yes |
| Observations | 353,220 | 353,220 | 353,220 |

⁵⁸⁶

^a A logistic regression was used for medication adherence. A linear regression was used for the average medication possession ratios. A negative binomial regression was used for the average number of days of antihypertensive drug supply. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of inperson visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with 95% CI (in parentheses) were reported. All standard errors were clustered by states.

^b Medication adherence was defined as a dummy indicator, where = 1 if the average medication possession ratio of the seven antihypertensive therapeutic classes is $\geq 80\%$, otherwise = 0.

596 Table 3. The association of <u>telehealth coverage parity laws</u> with medication adherence,

medication possession ratios, and average number of drug supply per antihypertensive
 drug, 2018–2021.^a

| | Average Medication Possession Ratios (%) | Medication Adherence (%) ^b | Average days of drug supply |
|----------------------------|---|--|--------------------------------|
| | | | |
| Coverage parity | 0.26 (-0.14 - 0.66) | 0.10 (-0.36 - 0.56) | 2.13* (0.19 - 4.07) |
| Covariates | (| (| (0022 0001) |
| COVID-19 diagnosis | -1 69*** | -3 57*** | -2 20*** |
| | (-1.961.42) | (-4.033.11) | (-3.131.27) |
| Number of in-person visits | 0.05*** | -0.00 | -0.15*** |
| | (0.04 - 0.07) | (-0.02 - 0.02) | (-0.170.13) |
| Aged 18-34 [reference] | | (0.02 0.02) | |
| Aged 35–44 | 9 83*** | 9 33*** | 16 96*** |
| ngou 35 Th | (9.09 - 10.57) | (8.56 - 10.10) | (15.69 - 18.23) |
| Aged 45-54 | 17 07*** | 17 90*** | 27 04*** |
| | (16.33 - 17.82) | (17.118.60) | (25.49 - 28.59) |
| Aged 55–64 | 21 21*** | 23 90*** | 31 55*** |
| | (20.31 - 22.11) | (23.00 - 24.70) | (29.41 - 33.70) |
| Male [reference] | (20.01 22.11) | | |
| Female | -2.93*** | -3.95*** | -9.20*** |
| | (-3.252.60) | (-4.363.54) | (-10.168.24) |
| Rural [reference] | (0.20 2.00) | | |
| Urban | 0.24 | -0.41 | 6 98*** |
| | (-0.34 - 0.81) | (-1.09 - 0.27) | (3.50 - 10.46) |
| Comorbidities | | (1.0) 0.2/) | |
| Myocardial infarction | -1.57*** | -0.81 | -18 46*** |
| | (-2.410.73) | (-1.92 - 0.31) | (-20.0116.90) |
| Congestive heart failure | -1.24*** | -2.88*** | -23.52*** |
| | (-1.850.63) | (-3.712.05) | (-25.1321.90) |
| Cerebrovascular | -0.75* | -0.86 | -10.18*** |
| | (-1.380.11) | (-1.73 - 0.01) | (-11.349.012) |
| Peripheral vascular | -3.03*** | -2.97*** | -13.01*** |
| F | (-4.391.66) | (-4.471.46) | (-15.5210.49) |
| Dementia | -11.15** | -10.00** | -33.01*** |
| | (-17.834.47) | (-16.703.33) | (-44.9021.11) |
| Chronic pulmonary disease | -2.71*** | -3.46*** | -6.37*** |
| | (-3.162.25) | (-4.002.93) | (-7.265.49) |
| Rheumatic disease | -1.57*** | -2.26*** | -4.50*** |
| | (-2.410.74) | (-3.291.22) | (-6.332.66) |

| Peptic ulcer disease | -7.84*** | -9.36*** | -16.52*** |
|-----------------------------|----------------|----------------|----------------|
| | (-9.186.49) | (-11.07.70) | (-19.9513.08) |
| Mild liver disease | -2.79*** | -2.42*** | -6.12*** |
| | (-3.512.06) | (-3.361.48) | (-7.904.34) |
| Diabetes without chronic | 1.60*** | 1.46*** | 8.56*** |
| complication | (1.34 - 1.87) | (1.07 - 1.85) | (7.73 - 9.39) |
| Diabetes with chronic | -1.37*** | -2.04*** | -1.63*** |
| complication | (-1.830.91) | (-2.671.42) | (-2.390.88) |
| Hemiplegia or paraplegia | -3.63** | -2.73* | -13.36*** |
| | (-6.320.93) | (-5.180.28) | (-19.097.64) |
| Renal disease | -0.24 | -2.01*** | -14.09*** |
| | (-0.84 - 0.35) | (-2.721.31) | (-15.9112.28) |
| Any malignancy | 0.72 | 1.66*** | -0.11 |
| | (-0.01 - 1.46) | (0.846 - 2.47) | (-1.49 - 1.27) |
| Moderate or severe liver | -7.14*** | -9.99*** | -36.23*** |
| disease | (-11.073.20) | (-14.006.01) | (-43.1829.29) |
| Metastatic solid tumor | -7.11*** | -7.11*** | -13.71*** |
| | (-8.635.59) | (-8.995.22) | (-18.758.68) |
| AIDS/HIV | 2.35** | 2.94*** | -7.88*** |
| | (0.62 - 4.07) | (1.19 - 4.70) | (-11.783.982) |
| State-year level covariates | | | |
| Unemployment rates | 0.19* | 0.30* | -0.05 |
| | (0.03 - 0.36) | (0.05 - 0.55) | (-0.71 - 0.61) |
| GDP per capita | -0.00 | -0.00 | -0.00 |
| | (-0.00 – 0.00) | (-0.00 – 0.00) | (-0.00 – 0.00) |
| Poverty rates | -0.00 | 0.03 | -0.26* |
| | (-0.11 - 0.11) | (-0.12 - 0.18) | (-0.490.03) |
| | | | |
| State fixed effects | Yes | Yes | Yes |
| Year fixed effects | Yes | Yes | Yes |
| Observations | 353,220 | 353,220 | 353,220 |

^a A logistic regression was used for medication adherence. A linear regression was used for the average medication possession ratios. A negative binomial regression was used for the average number of days of antihypertensive drug supply. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of inperson visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with

605 95% CI (in parentheses) were reported. All standard errors were clustered by states.

606 ^b Medication adherence was defined as a dummy indicator, where = 1 if the average medication possession ratio of 607 the seven antihypertensive therapeutic classes is $\ge 80\%$, otherwise = 0.

Appendix Table 1. ICD-10-CM diagnosis codes for hypertension and ICD-10-CM diagnosis, procedure, and DRG codes for pregnancy

| | ICD-10-CM | DRG | ICD-10-PCS |
|---------------------------|--|---|---|
| Hypertension | I10-I15 | NA | NA |
| Cardiovascular disease | I00-I78 | NA | NA |
| Pregnancy | 000-099, 09A1- 09A5, Z33, Z34, Z36, Z37, Z3201, Z322, Z39, F53, A34 | 765, 766, 767, 768, 769, 770, 771, 772, 773, 775, 776, 777, 779, 780, 781, 782 | 10A0, 10D00Z0, 10D00Z1, 10D00Z2, 10D07Z3, 10D07Z4, 10D07Z5, 10D07Z6, 10D07Z7, 10D07Z8, 10E0XZZ |

Abbreviations: DRG, diagnosis-related group; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; ICD-10-PCS, International Classification of Diseases, Tenth Revision, Procedure Coding System

NA indicates not available.

| Therapeutic Class | Antihypertensive Medications |
|-------------------------|-------------------------------|
| A CE inhibitor | Antihypertensive inculcations |
| ACE IIIIIDITOR | Denazepiii |
| | Bepfidii Gentemril |
| | |
| | Enalapril |
| | Fosinopril |
| | Lisinopril |
| | Moexipril |
| | Perindopril |
| | Quinapril |
| | Ramipril |
| | Trandolapril |
| Angiotensin receptor | Azilsartan |
| blocker | Candesartan |
| | Eprosartan |
| | Irbesartan |
| | Losartan |
| | Olmesartan |
| | Telmisartan |
| | Valsartan |
| Beta blocker | Acebutolol |
| | Atenolol |
| | Betaxolol |
| | Bisoprolol |
| | Carvedilol |
| | Labetalol |
| | Metoprolol succinate |
| | Metoprolol tartrate |
| | Nadolol |
| | Nebivolol |
| | Pindolol |
| | Propranolol |
| Calcium channel blocker | Amlodipine |
| | Diltiazem |
| | Felodipine |
| | Isradinine |
| | Levamlodinine |
| | Nicardinine |
| | Nifedinine |
| | Nisoldinine |
| | Veranamil |
| Diuretic | Amiloride |
| | Bumetanida |
| | Chlorothiogida |
| | Chlorithalidana |
| | I CHIOFHIAIIdONE |

Appendix Table 2. Antihypertensives by therapeutic class

| | Furosemide |
|--------------------------|---------------------|
| | Hydrochlorothiozido |
| | Independe |
| | Methyalothiozida |
| | Metalazana |
| | Transmitte |
| | Torsemide |
| | Triamterene |
| Other antihypertensives | Clonidine |
| | Doxazosin |
| | Eplerenone |
| | Guanabenz |
| | Guanfacine |
| | Hydralazine |
| | Methyldopa |
| | Minoxidil |
| | Prazosin |
| | Spironolactone |
| | Terazosin |
| Renin-angiotensin system | Aliskiren |
| antagonists ^a | Azilsartan |
| | Benazepril |
| | Bepridil |
| | Candesartan |
| | Captopril |
| | Enalapril |
| | Eprosartan |
| | Fosinopril |
| | Irbesartan |
| | Lisinopril |
| | Losartan |
| | Moexipril |
| | Olmesartan |
| | Perindopril |
| | Quinapril |
| | Ramipril |
| | Telmisartan |
| | Trandolapril |
| | Valsartan |

^a Renin-angiotensin system antagonists are a composite therapeutic class consisting of ACE inhibitors, angiotensin receptor blockers, and aliskiren.

Appendix Table 3. State telehealth payment and coverage parity laws in effect January 1, 2018 – December 31, 2021

| State | 2018 | 2019 | 2020 | 2021 |
|---------------|----------|----------|----------|----------|
| Alabama | None | None | None | None |
| Alaska | None | None | Coverage | Coverage |
| Arizona | Coverage | Coverage | Coverage | Both |
| Arkansas | Both | Both | Both | Both |
| California | None | None | None | Both |
| Colorado | Coverage | Coverage | Both | Both |
| Connecticut | Coverage | Coverage | Coverage | Both |
| Delaware | Both | Payment | Both | Payment |
| District of | Coverage | Coverage | Coverage | Coverage |
| Columbia | | | | |
| Florida | None | None | None | None |
| Georgia | None | None | Both | Both |
| Hawaii | Payment | Payment | Payment | Payment |
| Idaho | None | None | None | None |
| Illinois | None | None | None | Both |
| Indiana | Coverage | Coverage | Coverage | Coverage |
| Iowa | None | Coverage | Coverage | Coverage |
| Kansas | None | None | None | None |
| Kentucky | None | Both | Both | Both |
| Louisiana | None | None | None | Coverage |
| Maine | Coverage | Coverage | Coverage | Coverage |
| Maryland | None | None | Coverage | Both |
| Massachusetts | Coverage | Coverage | Coverage | Coverage |
| Michigan | None | None | None | None |
| Minnesota | Both | Both | Both | Coverage |
| Mississippi | Coverage | Coverage | Coverage | Both |
| Missouri | Both | Both | Both | Both |
| Montana | Coverage | Coverage | Coverage | Coverage |
| Nebraska | Coverage | Coverage | Coverage | Coverage |
| Nevada | Coverage | Coverage | Coverage | Both |
| New | Coverage | Coverage | Both | Both |
| Hampshire | | | | |
| New Jersey | Both | Both | Both | Both |
| New Mexico | Coverage | Both | Both | Coverage |
| New York | Coverage | Coverage | Coverage | Coverage |
| North | None | None | None | None |
| Carolina | 0 | 0 | 0 | 0 |
| North Dakota | Coverage | Coverage | Coverage | Coverage |
| Ohio | None | Coverage | Coverage | Coverage |

| Oklahoma | None | None | None | Both |
|---------------------|----------|----------|----------|----------|
| Oregon | Coverage | Coverage | Coverage | Coverage |
| Pennsylvania | None | None | None | None |
| Rhode Island | Coverage | Coverage | Both | Both |
| South | None | None | None | None |
| Carolina | | | | |
| South Dakota | None | Coverage | Coverage | Coverage |
| Tennessee | Coverage | Coverage | Coverage | Coverage |
| Texas | None | None | None | None |
| Utah | None | None | None | Coverage |
| Vermont | Coverage | Coverage | Coverage | Coverage |
| Virginia | Both | Both | Both | Both |
| Washington | None | None | Payment | Payment |
| West Virginia | None | None | Coverage | Coverage |
| Wisconsin | None | None | None | None |
| Wyoming | None | None | None | None |

Note: *None* indicates no relevant telehealth payment or coverage parity laws identified during the respective years. *Both* indicates telehealth payment and coverage parity laws were in effect during the respective years.

| Appendix Table 4. Identification of outpatient telehealth encounters | |
|--|--|
| | |

| Description | Value |
|---|--------------------|
| Place of Service | =2 |
| | (i.e., telehealth) |
| Procedure Modifier | |
| Synchronous telemedicine service rendered via telephone or other real- | =93 |
| time interactive audio-only telecommunications system | |
| Synchronous telemedicine service rendered via real-time interactive | =95 |
| audio and visual telecommunication system | |
| Telehealth services for diagnosis, evaluation, or treatment of symptoms | =GO |
| of acute stroke | |
| Telehealth service rendered via asynchronous telecommunications | =GQ |
| system | |
| Telehealth service rendered via interactive audio and video | =GT |
| telecommunication systems | |

| States | Freq. | Percent % |
|----------------|--------|-----------|
| Alabama | 23,499 | 6.65 |
| Alaska | 169 | 0.05 |
| Arizona | 6,659 | 1.89 |
| Arkansas | 1,663 | 0.47 |
| California | 12,967 | 3.67 |
| Colorado | 2,552 | 0.72 |
| Connecticut | 3,577 | 1.01 |
| Delaware | 1,680 | 0.48 |
| Florida | 22,778 | 6.45 |
| Georgia | 22,904 | 6.48 |
| Hawaii | 38 | 0.01 |
| Idaho | 381 | 0.11 |
| Illinois | 11,347 | 3.21 |
| Indiana | 10,754 | 3.04 |
| Iowa | 1,313 | 0.37 |
| Kansas | 2,449 | 0.69 |
| Kentucky | 22,911 | 6.49 |
| Louisiana | 3,577 | 1.01 |
| Maine | 1,100 | 0.31 |
| Maryland | 6,254 | 1.77 |
| Massachusetts | 7,049 | 2.00 |
| Michigan | 24,050 | 6.81 |
| Minnesota | 1,865 | 0.53 |
| Mississippi | 5,024 | 1.42 |
| Missouri | 6,532 | 1.85 |
| Montana | 296 | 0.08 |
| Nebraska | 709 | 0.20 |
| Nevada | 903 | 0.26 |
| New Hampshire | 740 | 0.21 |
| New Jersey | 9,713 | 2.75 |
| New Mexico | 328 | 0.09 |
| New York | 12,160 | 3.44 |
| North Carolina | 14,250 | 4.03 |
| North Dakota | 174 | 0.05 |
| Ohio | 21,958 | 6.22 |
| Oklahoma | 2,739 | 0.78 |
| Oregon | 5,117 | 1.45 |
| Pennsylvania | 13,663 | 3.87 |
| Rhode Island | 515 | 0.15 |
| South Carolina | 4,741 | 1.34 |
| South Dakota | 572 | 0.16 |
| Tennessee | 9.541 | 2.70 |

Appendix Table 5. Distribution of sample by 50 states and the District of Columbia.

| Texas | 29,030 | 8.22 |
|-----------------------------|---------|------|
| Utah | 800 | 0.23 |
| Vermont | 478 | 0.14 |
| Virginia | 12,818 | 3.63 |
| Washington | 2,975 | 0.84 |
| District of Columbia | 441 | 0.12 |
| West Virginia | 2,140 | 0.61 |
| Wisconsin | 3,119 | 0.88 |
| Wyoming | 208 | 0.06 |
| Total | 353,220 | 100 |

Appendix Table 6. The association of <u>telehealth payment parity</u> laws with number of hypertension-related telehealth and in-person visits.^a

| | Number of hypertension-related telehealth visits per 1,000 patients | Number of CVD- related telehealth visits per 1,000 patients |
|----------------------------|--|--|
| | | |
| Payment parity | 2.61** | 0.92** |
| | (0.99 - 4.23) | (0.23 - 1.61) |
| Covariates | | |
| COVID-19 diagnosis | 111.80*** | 21.13*** |
| | (107.80 - 115.80) | (19.36 - 22.90) |
| Number of in-person visits | 0.48*** | 0.29*** |
| | (0.44 - 0.52) | (0.27 - 0.31) |
| Aged 18–34 [reference] | | |
| Aged 35–44 | 5.89** | 7.63*** |
| | (2.35 - 9.43) | (5.48 - 9.79) |
| Aged 45–54 | -3.90* | 13.32*** |
| | (-7.250.55) | (11.14 - 15.50) |
| Aged 554 | -8.93*** | 18.62*** |
| | (-12.385.48) | (16.26 - 20.97) |
| Male [reference] | | |
| Female | 14.79*** | -5.55*** |
| | (13.41 - 16.16) | (-6.244.85) |
| Rural [reference] | | |
| Urban | 31.22*** | 6.51*** |
| | (29.08 - 33.36) | (5.53 - 7.49) |
| Comorbidities | | |
| Myocardial infarction | -7.53** | 22.05*** |
| | (-12.722.34) | (20.10 - 24.00) |
| Congestive heart failure | 2.76 | 26.87*** |
| | (-1.51 - 7.04) | (24.77 - 28.97) |
| Cerebrovascular | 5.84* | 18.36*** |
| | (1.17 - 10.51) | (16.60 - 20.13) |
| Peripheral vascular | 6.67 | 16.22*** |
| | (-0.87 - 14.21) | (13.79 - 18.65) |
| Dementia | -4.72 | 3.72 |
| | (-42,64 - 33,20) | (-9.24 - 16.68) |
| Chronic pulmonary disease | 12.18*** | 5 98*** |
| | (9.82 - 14.53) | (4.98 - 6.97) |
| Rheumatic disease | 15 21*** | 10.97*** |
| | (10.44 - 19.99) | (9.10 - 12.84) |
| Pentic ulcer disease | _3.87 | _2 04 |
| | (-14 43 - 6 78) | (-5.07) |
| Mild liver disease | (۲۵, ۲۵, ۲۵, ۲۵, ۲۵) ۲ ۸ ۸ ۸ ۸ ۲۰ ۲ ۲ ۲۰ | 0.12 |
| 1111U 11VEI UISEASE | 0.00 | 0.15 |

| | (2.21 - 9.94) | (-1.45 - 1.72) |
|-----------------------------|-----------------|----------------|
| Diabetes without chronic | | |
| complication | 18.25*** | 1.77*** |
| | (16.54 - 19.95) | (1.05 - 2.49) |
| Diabetes with chronic | | |
| complication | 11.84*** | 3.55*** |
| | (8.72 - 14.95) | (2.33 - 4.78) |
| Hemiplegia or paraplegia | 3.80 | 10.35*** |
| | (-7.92 - 15.51) | (6.94 - 13.76) |
| Renal disease | 57.78*** | 0.30 |
| | (54.15 - 61.40) | (-1.05 - 1.64) |
| Any malignancy | 0.97 | 1.50* |
| | (-2.70 - 4.63) | (0.03 - 2.97) |
| Moderate or severe liver | | |
| disease | -12.95 | 0.43 |
| | (-30.21 - 4.30) | (-5.34 - 6.19) |
| Metastatic solid tumor | 5.38 | -0.92 |
| | (-6.27 - 17.02) | (-5.44 - 3.61) |
| AIDS/HIV | 64.51*** | 7.53*** |
| | (54.48 - 74.53) | (3.18 - 11.88) |
| State-year level covariates | | |
| Unemployment rates | -0.13 | -0.12 |
| | (-0.94 - 0.67) | (-0.45 - 0.22) |
| GDP per capita | -0.00*** | -0.00 |
| | (-0.000.00) | (-0.00 - 0.00) |
| Poverty rates | 0.24 | 0.09 |
| | (-0.22 - 0.70) | (-0.11 - 0.29) |
| | | |
| State fixed effects | Yes | Yes |
| Year fixed effects | Yes | Yes |
| Observations | 353,220 | 353,220 |

Abbreviation: CVD, cardiovascular disease.

^a An exponential hurdle model was used for the number of hypertension- and CVD-related telehealth visits per 1,000 patients. Hypertension- and CVD-related telehealth visits were defined if the visits contained a diagnosis of hypertension (ICD-10-CM=I10-I15) and CVD (ICD-10-CM=I00-I78), respectively. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with 95% CI (in parentheses) were reported. All standard errors were clustered by states.

Appendix Table 7. The association of telehealth <u>coverage parity laws</u> with number of hypertension-related telehealth and in-person visits.^a

| | Number of hypertension-related telehealth visits per 1,000 patients | Number of CVD- related telehealth visits per 1,000 patients |
|----------------------------|--|--|
| | | |
| Coverage parity | 1.49 | 0.76 |
| | (-0.47 - 3.45) | (-0.04 - 1.56) |
| Covariates | | |
| COVID-19 diagnosis | 111.80*** | 21.09*** |
| | (107.80 - 115.70) | (19.33 - 22.85) |
| Number of in-person visits | 0.48*** | 0.29*** |
| | (0.44 - 0.52) | (0.27 - 0.31) |
| Aged 18-–4 [reference] | | |
| Aged 35–44 | 5.89** | 7.62*** |
| | (2.35 - 9.43) | (5.47 - 9.77) |
| Aged 45–54 | -3.90* | 13.30*** |
| | (-7.250.54) | (11.13 - 15.47) |
| Aged 55–64 | -8.93*** | 18.58*** |
| | (-12.385.47) | (16.24 - 20.93) |
| Male [reference] | | , , , |
| Female | 14.79*** | -5.54*** |
| | (13.41 - 16.16) | (-6.234.84) |
| Rural [reference] | | (/ |
| Urban | 31.22*** | 6.49*** |
| | (29.08 - 33.36) | (5.52 - 7.47) |
| Comorbidities | | (0.02) |
| Myocardial infarction | -7.53** | 22.01*** |
| | (-12,72,2,34) | (20.06 - 23.95) |
| Congestive heart failure | 2.77 | 26.83*** |
| | (-1.50 - 7.04) | (24 74 - 28 92) |
| Cerebrovascular | 5 83* | 18 33*** |
| | (1.16 - 10.49) | (16.57 - 20.08) |
| Peripheral vascular | 6.68 | 16 10*** |
| | (0.86 ± 14.22) | (13.76 18.61) |
| Domontio | (-0.80 - 14.22) | 2 70 |
| Dementia | -4.71 | 5.70 |
| Chronia nulmonomy diagona | (-42.03 - 33.21) | (-9.24 - 10.03) |
| Chronic pullionary disease | 12.1/2000 | $\frac{3.77}{(1.09)}$ |
| Dhaumatis disses | (9.82 - 14.33) | (4.98 - 0.90) |
| Kneumatic disease | 15.22*** | 10.95*** |
| | (10.44 - 19.99) | (9.08 - 12.82) |
| Peptic ulcer disease | -3.82 | -2.04 |
| | (-14.42 - 6.78) | (-5.99 - 1.91) |
| Mild liver disease | 6.08** | 0.14 |

| | (2.22 - 9.94) | (-1.45 - 1.72) |
|-----------------------------|-----------------|----------------|
| Diabetes without chronic | | |
| complication | 18.25*** | 1.77*** |
| | (16.54 - 19.95) | (1.05 - 2.49) |
| Diabetes with chronic | | |
| complication | 11.83*** | 3.54*** |
| | (8.72 - 14.95) | (2.32 - 4.77) |
| Hemiplegia or paraplegia | 3.78 | 10.33*** |
| | (-7.93 - 15.49) | (6.92 - 13.73) |
| Renal disease | 57.78*** | 0.30 |
| | (54.15 - 61.40) | (-1.05 - 1.64) |
| Any malignancy | 0.97 | 1.50* |
| | (-2.70 - 4.64) | (0.03 - 2.97) |
| Moderate or severe liver | | |
| disease | -12.97 | 0.43 |
| | (-30.22 - 4.29) | (-5.32 - 6.18) |
| Metastatic solid tumor | 5.38 | -0.92 |
| | (-6.27 - 17.02) | (-5.43 - 3.60) |
| AIDS/HIV | 64.51*** | 7.53*** |
| | (54.49 - 74.54) | (3.19 - 11.86) |
| State-year level covariates | | |
| Unemployment rates | 0.08 | -0.04 |
| | (-0.72 - 0.88) | (-0.37 - 0.29) |
| GDP per capita | -0.00** | -0.00 |
| | (-0.000.00) | (-0.00 - 0.00) |
| Poverty rates | 0.26 | 0.09 |
| | (-0.21 - 0.74) | (-0.12 - 0.29) |
| | | |
| State fixed effects | Yes | Yes |
| Year fixed effects | Yes | Yes |
| Observations | 353,220 | 353,220 |

Abbreviation: CVD, cardiovascular disease.

^a An exponential hurdle model was used for the number of hypertension- and CVD-related telehealth visits. Hypertension- and CVD-related telehealth visits were defined if the visits contained a diagnosis of hypertension (ICD-10-CM=I10-I15) and CVD (ICD-10-CM=I00-I78), respectively. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with 95% CI (in parentheses) were reported. All standard errors were clustered by states. **Appendix Table 8.** Sensitivity analyses of the association of telehealth payment and coverage parity laws with medication adherence, 2018–2021.^a

| Sensitivity analysis | Probit | OLS | Probit | OLS |
|----------------------|-----------------|-----------------|----------------|-----------------|
| | Medication | Medication | Medication | Medication |
| | Adherence | Adherence | Adherence | Adherence |
| | | | | |
| Payment parity | 0.46* | 0.46* | NA | NA |
| | (0.01- 0.92) | (0.01 - 0.92) | | |
| Coverage parity | NA | | 0.10 | 0.10 |
| | | | (-0.37 - 0.57) | (-0.37 - 0.57) |
| Covariates | | | | |
| COVID-19 | | | | |
| diagnosis | -3.60*** | -3.60*** | -3.61*** | -3.61*** |
| | | | (-4.06 | |
| | (-4.063.15) | (-4.063.15) | 3.15) | (-4.063.15) |
| Number of in- | | | | |
| person visits | -0.00 | -0.00 | -0.00 | -0.00 |
| | (-0.02 - 0.02) | (-0.02 - 0.02) | (-0.02 - 0.02) | (-0.02 - 0.02) |
| Aged 18–34 | | | | |
| [reference] | | | | |
| Aged 35–44 | 9.69*** | 9.69*** | 9.69*** | 9.69*** |
| | | | (8.84 – | |
| | (8.84 - 10.50) | (8.84 - 10.53) | 10.50) | (8.84 - 10.53) |
| Aged 45–54 | 18.50*** | 18.53*** | 18.50*** | 18.53*** |
| | | | (17.70 – | |
| | (17.70 – 19.30) | (17.74 - 19.33) | 19.30) | (17.74 - 19.33) |
| Aged 55–64 | 24.40*** | 24.44*** | 24.40*** | 24.44*** |
| | | | (23.50 – | |
| | (23.50 - 25.40) | (23.48 - 25.39) | 25.40) | (23.48 - 25.39) |
| Male [reference] | | | | |
| Female | -3.96*** | -3.96*** | -3.96*** | -3.96*** |
| | | | (-4.41 | |
| | (-4.413.51) | (-4.413.51) | 3.51) | (-4.413.51) |
| Rural [reference] | | | | |
| Urban | -0.41 | -0.41 | -0.41 | -0.41 |
| | (-1.10 - 0.28) | (-1.10 - 0.28) | (-1.10 - 0.28) | (-1.10 - 0.28) |
| Comorbidities | | | | |
| Myocardial | | | | |
| infarction | -0.81 | -0.81 | -0.81 | -0.81 |
| | (-1.94 - 0.33) | (-1.94 - 0.33) | (-1.94 - 0.33) | (-1.94 - 0.33) |
| Congestive heart | | | | |
| failure | -2.90*** | -2.90*** | -2.90*** | -2.90*** |
| | | | (-3.77 | |
| | (-3.772.03) | (-3.772.03) | 2.03) | (-3.772.03) |

| Cerebrovascular | -0.85 | -0.85 | -0.85 | -0.85 |
|----------------------|----------------|----------------|----------------|----------------|
| | (-1.75 - 0.04) | (-1.75 - 0.04) | (-1.75 - 0.04) | (-1.75 - 0.04) |
| Peripheral vascular | -3.01*** | -3.01*** | -3.01*** | -3.01*** |
| | | | (-4.56 | |
| | (-4.561.46) | (-4.561.46) | 1.46) | (-4.561.46) |
| Dementia | -10.20** | -10.22** | -10.2** | -10.22** |
| | | | (-17.30 | (-17.29 |
| | (-17.303.15) | (-17.293.15) | 3.15) | 3.15) |
| Chronic pulmonary | | | | |
| disease | -3.50*** | -3.50*** | -3.50*** | -3.50*** |
| | | | (-4.05 | |
| | (-4.052.95) | (-4.052.95) | 2.95) | (-4.052.95) |
| Rheumatic disease | -2.30*** | -2.30*** | -2.30*** | -2.30*** |
| | | | (-3.39 | |
| | (-3.391.22) | (-3.391.22) | 1.22) | (-3.391.22) |
| Peptic ulcer disease | -9.59*** | -9.59*** | -9.59*** | -9.59*** |
| | | | (-11.3 | (-11.34 |
| | (-11.07.84) | (-11.347.84) | 7.84) | 7.84) |
| Mild liver disease | -2.44*** | -2.44*** | -0.0244*** | -2.44*** |
| | | | (-3.41 | |
| | (-3.411.47) | (-3.411.47) | 1.47) | (-3.411.47) |
| Diabetes without | | | | |
| chronic complication | 1.45*** | 1.45*** | 1.45*** | 1.45*** |
| | (1.05 - 1.84) | (1.05 - 1.84) | (1.05 – 1.84) | (1.05 - 1.84) |
| Diabetes with | | | | |
| chronic complication | -2.04*** | -2.04*** | -2.03*** | -2.03*** |
| | | | (-2.68 | |
| | (-2.681.39) | (-2.681.39) | 1.39) | (-2.681.39) |
| Hemiplegia or | | | | |
| paraplegia | -2.78* | -2.78* | -2.78* | -2.78* |
| | | | (-5.35 | |
| | (-5.352.21) | (-5.350.22) | 0.22) | (-5.350.22) |
| Renal disease | -2.02*** | -2.02*** | -2.02*** | -2.02*** |
| | | | (-2.75 | |
| | (-2.751.29) | (-2.751.29) | 1.29) | (-2.751.29) |
| Any malignancy | 1.63*** | 1.63*** | 1.63*** | 1.63*** |
| | (0.82 - 2.45) | (0.82 - 2.45) | (0.82 - 2.45) | (0.82 - 2.45) |
| Moderate or severe | | | | |
| liver disease | -10.2*** | -10.21*** | -10.2*** | -10.21*** |
| | | | (-14.40 | (-14.37 |
| | (-14.406.04) | (-14.376.04) | 6.04) | 6.04) |
| Metastatic solid | | | | |
| tumor | -7.18*** | -7.18*** | -7.18*** | -7.18*** |
| | | | (-9.14 | |
| | (-9.145.22) | (-9.145.22) | 5.22) | (-9.145.22) |

| AIDS/HIV | 2.94** | 2.94** | 2.94** | 2.94** |
|---------------------|----------------|----------------|----------------|----------------|
| | (1.16 - 4.72) | (1.16 - 4.72) | (1.16 - 4.72) | (1.16 - 4.72) |
| State-year level | | | | |
| covariates | | | | |
| Unemployment | | | | |
| rates | 0.31* | 0.31* | 0.30* | 0.29* |
| | (0.06 - 0.56) | (0.06 - 0.56) | (0.04 - 0.55) | (0.04 - 0.55) |
| GDP per capita | -0.00 | -0.00 | -0.00 | -0.00 |
| | (-0.00 - 0.00) | (-0.00 - 0.00) | (-0.00 - 0.00) | (-0.00 - 0.00) |
| Poverty rates | 0.04 | 0.04 | 0.03 | 0.03 |
| | (-0.11 - 0.19) | (-0.11 - 0.19) | (-0.12 - 0.18) | (-0.12 - 0.18) |
| | | | | |
| State fixed effects | Yes | Yes | Yes | Yes |
| Year fixed effects | Yes | Yes | Yes | Yes |
| Observations | 353,220 | 353,220 | 353,220 | 353,220 |

Abbreviation: NA, not available.

^a A probit and OLS were used as sensitivity analyses for the medication adherence dependent variable. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with 95% CI (in parentheses) were reported. All standard errors were clustered by states.

| | ZINB | ZINB |
|----------------------------|-----------------|-----------------|
| | Average days of | Average days of |
| | drug supply | drug supply |
| | | |
| Payment parity | 1.88 | NA |
| | (-0.11 - 3.86) | |
| Coverage parity | NA | 1.92 |
| | | (-0.01 - 3.86) |
| Covariates | | |
| COVID-19 diagnosis | -3.49*** | -3.49*** |
| | (-4.472.51) | (-4.482.51) |
| Number of in-person visits | -0.10*** | -0.10*** |
| | (-0.130.07) | (-0.130.07) |
| Aged 18–34 [reference] | | |
| Aged 35–44 | 12.47*** | 12.47*** |
| | (11.38 - 13.56) | (11.38 - 13.56) |
| Aged 45–54 | 21.95*** | 21.95*** |
| | (20.51 - 23.39) | (20.51 - 23.39) |
| Aged 55–64 | 26.74*** | 26.74*** |
| | (24.68 - 28.79) | (24.68 - 28.80) |
| Male [reference] | | |
| Female | -9.14*** | -9.14*** |
| | (-10.108.19) | (-10.108.19) |
| Rural [reference] | | |
| Urban | 6.23*** | 6.23*** |
| | (3.01 - 9.45) | (3.01 - 9.45) |
| Comorbidities | | |
| Myocardial infarction | -18.62*** | -18.62*** |
| | (-20.1617.08) | (-20.1617.08) |
| Congestive heart failure | -23.53*** | -23.53*** |
| | (-25.2221.84) | (-25.2221.84) |
| Cerebrovascular | -10.40*** | -10.39*** |
| | (-11.569.231) | (-11.569.23) |
| Peripheral vascular | -12.99*** | -12.99*** |
| | (-15.3010.67) | (-15.3010.67) |
| Dementia | -29.33*** | -29.33*** |
| | (-39.3319.33) | (-39.3319.34) |
| Chronic pulmonary disease | -6.49*** | -6.49*** |
| | (-7.395.58) | (-7.395.58) |
| Rheumatic disease | -4.91*** | -4.91*** |
| | (-6.743.09) | (-6.743.09) |
| Peptic ulcer disease | -15.25*** | -15.24*** |

Appendix Table 9. Sensitivity analyses of the association of telehealth payment and coverage parity laws with average number of drug supply per antihypertensive drug, 2018–2021.^a

| | (-18.3712.12) | (-18.3712.11) |
|-----------------------------|----------------|----------------|
| Mild liver disease | -5.91*** | -5.91*** |
| | (-7.604.23) | (-7.604.23) |
| Diabetes without chronic | | |
| complication | 8.54*** | 8.54*** |
| | (7.76 - 9.33) | (7.76 - 9.33) |
| Diabetes with chronic | | |
| complication | -1.71*** | -1.71*** |
| | (-2.460.96) | (-2.460.96) |
| Hemiplegia or paraplegia | -12.89*** | -12.88*** |
| | (-18.187.60) | (-18.187.59) |
| Renal disease | -13.87*** | -13.86*** |
| | (-15.7711.96) | (-15.7711.96) |
| Any malignancy | -0.28 | -0.28 |
| | (-1.65 - 1.10) | (-1.65 - 1.10) |
| Moderate or severe liver | | |
| disease | -35.11*** | -35.11*** |
| | (-40.8229.41) | (-40.8229.41) |
| Metastatic solid tumor | -12.35*** | -12.35*** |
| | (-16.967.74) | (-16.967.74) |
| AIDS/HIV | -8.00*** | -8.00*** |
| | (-11.934.07) | (-11.934.07) |
| State-year level covariates | | |
| Unemployment rates | -0.28 | -0.22 |
| | (-1.00 - 0.43) | (-0.92 - 0.49) |
| GDP per capita | -0.00 | -0.00 |
| | (-0.00 - 0.00) | (-0.00 - 0.00) |
| Poverty rates | -0.21 | -0.29* |
| | (-0.44 - 0.02) | (-0.510.06) |
| | | |
| State fixed effects | Yes | Yes |
| Year fixed effects | Yes | Yes |
| Observations | 353,220 | 353,220 |

Abbreviations: ZINB, zero-inflated negative binomial; NA, not available.

^a A zero-inflated negative binomial model was used for sensitivity analysis. The logit model was used to model zero outcomes (first part). A negative binomial model was used to model the number of average days of drug supply (second part). The first part was adjusted for COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, and comorbidities. The second part was adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with 95% CI were reported. All standard errors were clustered by states.